Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BRIEF-Spectral Medical says Richard Wieland II Appointed Interim CFO

2018-02-01 reuters
* SPECTRAL MEDICAL INC - ‍RICHARD WIELAND II HAS BEEN APPOINTED AS INTERIM CFO.​ Source text for Eikon: Further company coverage:

FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump

2017-12-18 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 18, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the United States Food and Drug Administration ("FDA") has granted 510(k) clearance for the Spectral Apheresis Machine ("SAM") for use in continuous renal replacement therapy ("CRRT") and therapeutic plasma exchange ("TPE").

BRIEF-Spectral Medical To Launch Toraymyxin/EAA In Canada In Q1 2018

2017-12-13 reuters
* SPECTRAL MEDICAL INC - ENTERED DISTRIBUTION AGREEMENT WITH CASTER MEDICAL SYSTEM TO LAUNCH TORAYMYXIN AND EAA IN CANADA COMMENCING IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018

2017-12-13 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 13, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the company has entered into a distribution agreement with CASTER MEDICAL SYSTEM ("CMS") to launch Toraymyxin™ ("PMX") and EAA™ in Canada commencing in the first quarter of 2018. CMS's experienced sales team will promote the products in all parts of the country, with Spectral's team contributing scientific and marketing support.

Report Coverage on Healthcare Stocks, ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova

2017-11-16 accesswire
LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Medical Diagnostics & Research industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova.

Spectral Announces Third Quarter Results

2017-11-14 marketwired
TORONTO, ONTARIO--(Marketwired - Nov. 14, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced its unaudited financial results for the third quarter ended September 30, 2017. (15-0)

Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin(TM)

2017-10-31 marketwired
TORONTO, ONTARIO--(Marketwired - Oct. 31, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced the results of its recent meeting with the United States Food and Drug Administration ("FDA") concerning the status of its PMA application for Toraymyxin™. (15-0)

Spectral Announces Retirement of Chief Financial Officer

2017-10-18 marketwired
TORONTO, ONTARIO--(Marketwired - Oct. 18, 2017) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced that Tony Businskas will be retiring as the Executive Vice President and CFO of the Company on January 31, 2018, after 12 years of service to the Company.

Daily Coverage on Healthcare Stocks ProMIS Neurosciences Spectral Medical GeneNews and Sernova

2017-10-09 accesswire
LONDON, UK / ACCESSWIRE / October 9, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Medical Diagnostics & Research industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova.

Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum

2017-10-04 marketwired
TORONTO, ONTARIO--(Marketwired - Oct. 4, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, announced that, in a special plenary session this afternoon being held at the 2017 Canadian Critical Care Forum in Toronto, Dr. Paul Walker, President & CEO of Spectral, will deliver a presentation titled "Treatments for Septic Shock : New Insights from the EUPHRATES Trial.

Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin(TM)

2017-09-21 marketwired
TORONTO, ONTARIO--(Marketwired - Sept. 21, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced that, pursuant to the acceptance by the United States Food and Drug Administration ("FDA") of its PMA submission for Toraymyxin™ for filing on July 20, 2017, it has been engaged in an ongoing interactive review process with the FDA.

Spectral Announces Second Quarter Results

2017-08-11 marketwired
TORONTO, ONTARIO--(Marketwired - Aug. 11, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2017.

Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position

2017-08-04 seekingalpha
CytoSorbents and Spectral Medical Inc. are two medical device companies that have much in common. One is based in US and the other in Canada. CytoSorbents is in the business of reducing ICU deaths from fatal inflammation. Spectral Medical Inc. is in the business of treating sepsis, “life-threatening organ dysfunction caused by a dysregulated host response to infection.”, which is the leading cause of ICU deaths globally.

FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review

2017-07-24 marketwired
TORONTO, ONTARIO--(Marketwired - July 24, 2017) - Spectral Medical Inc. (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced that the United States Food and Drug Administration ( "FDA") has accepted its rolling PMA application for Toraymyxin™ ("PMX") for review.

The Reasons Why Spectral Medical's Sepsis Treatment Will Not Receive An FDA Approval

2017-07-23 seekingalpha
Spectral's sepsis treatment deals with only one factor, of questionable importance, in a highly complex medical condition.